{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemangiopericytoma&page=3", "query": { "condition": "Hemangiopericytoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemangiopericytoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemangiopericytoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T04:27:41.842Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00025675", "title": "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 105, "start_date": "2001-10-09", "completion_date": "2010-01-02", "has_results": false, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025675" }, { "nct_id": "NCT00348790", "title": "Vatalanib in Treating Patients With Recurrent or Progressive Meningioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Sarcoma" ], "interventions": [ { "name": "vatalanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-05", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 3, "location_summary": "Chicago, Illinois • Seattle, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348790" }, { "nct_id": "NCT04094610", "title": "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumors", "Metastatic Solid Tumors", "Lymphoma", "Primary CNS Tumors" ], "interventions": [ { "name": "Oral repotrectinib (TPX-0005)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 75, "start_date": "2020-03-12", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 20, "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04094610" }, { "nct_id": "NCT00006014", "title": "SU5416 in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "semaxanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2000-08", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-06-03", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 10, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006014" }, { "nct_id": "NCT00243074", "title": "S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Mesothelioma", "Epithelial Mesothelioma", "Recurrent Malignant Mesothelioma", "Sarcomatous Mesothelioma" ], "interventions": [ { "name": "cediranib maleate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2005-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243074" }, { "nct_id": "NCT07118176", "title": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Colorectal Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Lung Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Neoplasm of Unknown Primary", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Uterine Neoplasm", "Neuroendocrine Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Penile Carcinoma", "Pleural Carcinomatosis", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Salivary Gland Carcinoma", "Sarcoma", "Skin Carcinoma", "Solitary Fibrous Tumor", "Thymus Carcinoma", "Thyroid Gland Carcinoma", "Thyroid Gland Medullary Carcinoma", "Urothelial Carcinoma", "Vaginal Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-01", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118176" }, { "nct_id": "NCT01085630", "title": "Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "clinical observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2010-04", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2021-08-18", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 145, "location_summary": "Scottsdale, Arizona • San Francisco, California • Hartford, Connecticut + 104 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT01085630" }, { "nct_id": "NCT00499798", "title": "Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chemotherapeutic Agent Toxicity", "Infertility" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 16, "start_date": "2004-08", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499798" }, { "nct_id": "NCT01024907", "title": "Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Brain Tumor", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoma", "Adult Grade II Meningioma", "Adult Melanocytic Lesion", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Pineal Gland Astrocytoma", "Adult Pineocytoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "proton beam radiation therapy", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2009-12-17", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01024907" }, { "nct_id": "NCT02399371", "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Peritoneal Malignant Mesothelioma", "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Pleural Sarcomatoid Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-03-31", "completion_date": "2026-03-20", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-06T04:27:41.842Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399371" } ] }